“Medical consumables innovation helps patients with Alzheimer’s disease receive home treatment”
Lencanumab subcutaneous automatic injection pen was recently approved for use in the early initial treatment of Alzheimer’s disease (AD). This device achieves automatic, constant-rate injection through skin pressure, ensuring precise dosage. It is suitable for patients with vision impairment or insufficient hand strength, avoiding problems such as pain, drug reflux, and inaccurate dosing caused by manual injection. Its clinical efficacy is equivalent to weekly intravenous infusions. Patients can perform subcutaneous injections at home, eliminating the need for frequent visits to the clinic, thereby reducing care burdens and saving medical resources. Alzheimer’s disease is a major public health issue threatening the health of the elderly. This therapy has the potential to help achieve the goal of early treatment and slow down the progression of the disease.